arrow_back Back to App

Tax Credit for Research on Neurodegenerative and Psychiatric Conditions.

This law introduces a new 25% tax credit for companies and organizations conducting translational research into neurodegenerative diseases and psychiatric conditions. The goal is to accelerate the development of new treatments and devices, potentially leading to better and faster care for serious brain disorders. The credit is subject to an annual national cap and is available until the end of 2035.
Key points
A 25% tax credit is established for expenses related to research on mental health and neurological disorders (e.g., Alzheimer's, depression).
The incentive aims to speed up the creation of new therapeutics and devices targeting central nervous system disorders.
The total national credit allocation is capped, reaching up to $2 billion annually between 2027 and 2030, allocated based on scientific merit.
Tax-exempt entities (like non-profits or universities) can transfer the credit benefit to their private project partners to encourage public-private collaboration.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_2085
Sponsor: Rep. Thompson, Mike [D-CA-4]
Process start date: 2025-03-11
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Mental Health Research Accelerator Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_2085.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-03-11.

What are the main provisions?

Key points include:

  • A 25% tax credit is established for expenses related to research on mental health and neurological disorders (e.g., Alzheimer's, depression).
  • The incentive aims to speed up the creation of new therapeutics and devices targeting central nervous system disorders.
  • The total national credit allocation is capped, reaching up to $2 billion annually between 2027 and 2030, allocated based on scientific merit.
  • Tax-exempt entities (like non-profits or universities) can transfer the credit benefit to their private project partners to encourage public-private collaboration.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Thompson, Mike [D-CA-4].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Ways and Means.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Taxes Health